November 2024 – Talk Bio

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

5 months ago talkbio0Tagged BeiGene, Cancer Therapeutic Procedure, Commission approval, European (ethnic group), first-line, Gastroesophageal Junction Adenocarcinoma, Squamous cell carcinoma of esophagus, Stomach, Tevimbra, tislelizumab

TEVIMBRA, tislelizumab, European Commission approval, first-line treatment, esophageal squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, cancer treatment, BeiGene.

Merck and Kelun-Biotech Advance in Cancer Treatment with Exclusive License Agreement for Investigational ADC Candidates

5 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Immunostimulating conjugate (antigen), Kelun-Biotech, Malignant Neoplasms, Merck, NECTIN4 gene, SKB571, TROP2

Merck, Kelun-Biotech, Antibody-Drug Conjugates (ADC), Cancer Treatment, Exclusive License Agreement, TROP2, Nectin-4, SKB571

Novartis Announces 139 Layoffs in New Jersey Amid Ongoing Restructuring Efforts

5 months ago talkbio0Tagged Drug Industry, New Jersey, Novartis, restructuring

Novartis, layoffs, New Jersey, restructuring, pharmaceutical industry

Outlook Therapeutics to Resubmit BLA for ONS-5010 Despite Missing Primary Endpoint in NORSE EIGHT Trial

5 months ago talkbio0Tagged AMD, Approved, Attitude, Biologics License Application, Glycogen storage disease type II, Lytenava, New-onset refractory status epilepticus, United States Food and Drug Administration, Wet Age-Related Macular Degeneration

Outlook Therapeutics, ONS-5010, Lytenava, Wet Age-Related Macular Degeneration (wet AMD), Biologics License Application (BLA), NORSE EIGHT Trial, FDA Approval

Kronos Undergoes Major Restructuring: CEO Norbert Bischofberger Exits Amid 83% Workforce Reduction

5 months ago talkbio0Tagged Bischofberger, Industry, Kronos layoffs, Norbert, restructuring

Kronos layoffs, Norbert Bischofberger, biotech industry, workforce reduction, restructuring

Idorsia Pursues Strategic Licensing Deal for TRYVIO Amid Restructuring Efforts

5 months ago talkbio0Tagged financial strategy, Idorsia, restructuring, Tryvio

Idorsia, TRYVIO, aprocitentan, licensing deal, layoffs, restructuring, financial strategy

Acadia Pharmaceuticals Secures Exclusive Licensing Deal for Saniona’s Tremor Treatment Asset Worth Up to $582 Million

5 months ago talkbio0Tagged Acadia, biobucks, nervous system disorder, Saniona, Tremor

Acadia Pharmaceuticals, Saniona, tremor treatment, licensing deal, biobucks, neurological disorder

Philips and AWS Strengthen Strategic AI Partnership, Expanding Cloud-Enabled Diagnostics to Europe

5 months ago talkbio0Tagged Alagille Syndrome, Diagnostics, European (ethnic group), expansion, Generative AI, healthcare innovation, Integrated Diagnostics Portfolio, Philips, Strategic AI Collaboration

Philips, AWS, Strategic AI Collaboration, Cloud-Enabled Diagnostics, European Expansion, Healthcare Innovation, Integrated Diagnostics Portfolio, Generative AI Applications

Controversial Stanford Professor Jay Bhattacharya Nominated by Trump to Lead NIH Amid Criticism Over Pandemic Views

5 months ago talkbio0Tagged Administration occupational activities, Appointments, Bhattacharya, Controversial, COVID19 (disease), Critic, Jay, NIH Director Nomination, Pandemic Response, Professor, Public Health Research, Stanford University, Transplant Registry Unified Management Program

Jay Bhattacharya, NIH Director Nomination, COVID-19 Pandemic Response Critic, Stanford University Professor, Trump Administration, Public Health Research, Controversial Appointment

PTC Therapeutics Sells Priority Review Voucher for $150M Following Phase 2 ALS Trial Failure

5 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, factor IX, Failure (biologic function), Phase 2 trial, Priority Review

PTC Therapeutics, ALS, Phase 2 trial failure, priority review voucher, $150M sale